Correlation Between Sana Biotechnology and Sangamo Therapeutics
Can any of the company-specific risk be diversified away by investing in both Sana Biotechnology and Sangamo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sana Biotechnology and Sangamo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sana Biotechnology and Sangamo Therapeutics, you can compare the effects of market volatilities on Sana Biotechnology and Sangamo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sana Biotechnology with a short position of Sangamo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sana Biotechnology and Sangamo Therapeutics.
Diversification Opportunities for Sana Biotechnology and Sangamo Therapeutics
-0.81 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Sana and Sangamo is -0.81. Overlapping area represents the amount of risk that can be diversified away by holding Sana Biotechnology and Sangamo Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sangamo Therapeutics and Sana Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sana Biotechnology are associated (or correlated) with Sangamo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sangamo Therapeutics has no effect on the direction of Sana Biotechnology i.e., Sana Biotechnology and Sangamo Therapeutics go up and down completely randomly.
Pair Corralation between Sana Biotechnology and Sangamo Therapeutics
Given the investment horizon of 90 days Sana Biotechnology is expected to under-perform the Sangamo Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Sana Biotechnology is 1.06 times less risky than Sangamo Therapeutics. The stock trades about -0.09 of its potential returns per unit of risk. The Sangamo Therapeutics is currently generating about 0.27 of returns per unit of risk over similar time horizon. If you would invest 190.00 in Sangamo Therapeutics on September 19, 2024 and sell it today you would earn a total of 92.00 from holding Sangamo Therapeutics or generate 48.42% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
Sana Biotechnology vs. Sangamo Therapeutics
Performance |
Timeline |
Sana Biotechnology |
Sangamo Therapeutics |
Sana Biotechnology and Sangamo Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Sana Biotechnology and Sangamo Therapeutics
The main advantage of trading using opposite Sana Biotechnology and Sangamo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sana Biotechnology position performs unexpectedly, Sangamo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will offset losses from the drop in Sangamo Therapeutics' long position.Sana Biotechnology vs. Olema Pharmaceuticals | Sana Biotechnology vs. Cullinan Oncology LLC | Sana Biotechnology vs. Zentalis Pharmaceuticals Llc | Sana Biotechnology vs. X4 Pharmaceuticals |
Sangamo Therapeutics vs. Editas Medicine | Sangamo Therapeutics vs. Intellia Therapeutics | Sangamo Therapeutics vs. Bluebird bio | Sangamo Therapeutics vs. Alnylam Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |